Effects Of Dapagliflozin in Patients with Heart Failure - European Medical Journal

Effects Of Dapagliflozin in Patients with Heart Failure

1 Mins
New Nephrology Feature Image
Sherzod Abdullaev,1 *Olimkhon Sharapov2

The authors have declared no conflicts of interest.

EMJ Nephrol. ;:50
Dapagliflozin, ejection fraction, heart failure, sodium-glucose co-transporter inhibitor, Type 2 diabetes.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.


In the last few years, the effectiveness and role of drugs of the sodium–glucose co-transporter inhibitor group, or the so-called gliflozins in patients with Type 2 diabetes, are being actively studied.1-4 There are many works in the literature evaluating the effectiveness of gliflozins.5,6 This study is dedicated to the use of sodium–glucose co-transporter inhibitors in patients with chronic heart failure.


This study was a multi-centre prospective cohort study. The authors aimed to investigate the efficacy of dapagliflozin in patients with heart failure. Two hundred and twenty-five patients with Grade 3–4 heart failure with an ejection fraction <45% were selected. Patients received treatment with either dapagliflozin 10 mg or a placebo.


Initial results were received after 6 months. In the group of patients treated with dapagliflozin, a worsening of heart failure was observed in 36% fewer patients compared to the placebo group. Death from cardiovascular causes within 12 months in patients in the dapagliflozin group was observed almost two times less frequently than in patients in the placebo group.


The study’s authors found that among patients with heart failure and a reduced ejection fraction, the risk of worsening heart failure or death from cardiovascular events was lower among those who received dapagliflozin than among those who received the placebo, regardless of the presence or absence of diabetes. ●

Wiviott SD et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347-57. Neal B et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-57. Bhatt DL et al. The DAPA-HF trial: a momentous victory in the war against heart failure. Cell Metab. 2019;30(5):847-9. McDonald Lenahan C et al. SGLT2 inhibitors. Nurse Pract. 2021;46(7):30-7. Hsia DS et al. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Op Endocrinol Diabetes Obes. 2017;24(1);73-9. Daminov BT et al. Nephroprotective effects of sodium-glucose linked transporter-2 inhibitors. Clin Nephrol. 2020;4(12):75-9.

Keep your finger on the pulse

Join Now

Elevating the Quality of Healthcare Globally